InsiderTrades

Form 4 for MNPR Monopar Therapeutics

Accepted 2025-07-16 00:00:00 ET · period of report 2025-07-14 · accession 0001437749-25-022861 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-07-16 2025-07-14 MNPR Robinson Chandler CEO, Dir X - OptEx $0.01 +16.8K 90.3K +23% +$168
D 2025-07-16 2025-07-14 MNPR Robinson Chandler CEO, Dir S - Sale+OE $40.00 -16.8K 73.5K -19% -$672.0K
D 2025-07-16 2025-07-14 MNPR Robinson Chandler CEO, Dir X - OptEx $0.00 -16.8K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-07-14 X A 16,800 $0.01 90,272 D — — (F1) This transaction involved a cash exercise of stock options.
2 Common Common Stock 2025-07-14 S D 16,800 $40.00 73,472 D — — (F2) The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
3 Derivative Stock Options 2025-07-14 X D 16,800 $0.00 0 D $0.01 · — to 2027-02-20 16,800 Common Stock (F4) Reflects options to purchase up to 16,800 shares of common stock granted to Dr. Robinson on February 20, 2017, for his services as a director and officer of Monopar Therapeutics. The options vested 6/48ths upon the 6-month anniversary of the grant date and 1/48th per month thereafter.